Clinical Trials Browser

darolutamide × Head & Neck × Clear all

NCT05694819 2026-04-08

Darolutamide in Patients With Androgen Receptor-Positive Salivary Gland Carcinoma (DISCOVARY)

Phase 2 Completed

Salivary Gland Neoplasms, Bulbo-Spinal Atrophy, X-Linked

NCT05669664 2025-11-10

Testing the Anti-cancer Drug Darolutamide in Patients With Testosterone-Driven Salivary Gland Cancers

Phase 2 Active not recruiting

Salivary Gland Neoplasms